Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment

Molecular Cancer Therapeutics

Volumn 3, Issue 12, 2004, Pages 1551-1558

  Skvortsov, Sergej ^a   Sarg, Bettina ^b   Loeffler Ragg, Judith ^a   Skvortsova, Ira ^b   Lindner, Herbert ^b   Ott, Helmut Werner ^b   Lukas, Peter ^b   Illmensee, Karl ^b   Zwierzina, Heinz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CELL PROTEIN; CETUXIMAB; CHLORIDE CHANNEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FATTY ACID BINDING PROTEIN; GALECTIN 3; GLUTATHIONE TRANSFERASE; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; HEAT SHOCK PROTEIN 27; INORGANIC PYROPHOSPHATASE; ISOENZYME; MICROTUBULE ASSOCIATED PROTEIN; MONOCLONAL ANTIBODY; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; PROFILIN; PROTEASOME; PROTEIN KINASE C INHIBITOR; PROTEOME; UBIQUITIN THIOLESTERASE;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL METABOLISM; CELL PROLIFERATION; CELL STRAIN CACO 2; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TWO DIMENSIONAL ELECTROPHORESIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; PROTEOME; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 12344261777     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O'Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001;88:1352-6.
3. Ciardiello F, Kim N, Saeki T, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A 1991;88:7792-6.
4. O'Dwyer PJ, Benson AB III. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002;29:10-7.
5. Bogdan S, Klambt C. Epidermal growth factor receptor signaling. Curr Biol 2001;11:R292-5.
6. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
7. Liang K, Ang KK, Miles L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003; 57:246-54.
8. Kopp R, Rothbauer E, Mueller E, Schildberg FW, Jauch KW, Pfeiffer A. Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis Colon Rectum 2003;46:1391-9.
9. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001;37:S16-22.
10. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
11. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
12. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9.
13. Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998; 46:167-73.
14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract 1012]. Proc Am Soc Clin Oncol 2003;22:252.
15. Lutz MP, Schöffski P, Folprecht G, et al. A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR) [abstract 265PD]. Ann Oncol 2002;13:73.
16. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
17. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94:15-21.
18. Reed JC. Bcl-2 family proteins. Oncogene 1998;17:3225-36.
19. Ott HW, Lindner H, Sarg B, et al. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003;63:7507-14.
20. Mendelsohn J, Shin DM, Donato N, et al. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC) [abstract 1502]. Proc Am Soc Clin Oncol 1999;18:389.
21. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99-101.
22. Rubin MS, Shin DM, Pasmantier M, et al. Monoclonal antibody (MOAB) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients (PTS) with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens [abstract 1860]. Proc Am Soc Clin Oncol 2000;19:498.
23. Bonner JA, Ezekiel MP, Robert F, Meredith RF, Spencer SA, Waksal HW. Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies [abstract 5F]. Proc Am Soc Clin Oncol 2000;19:79.
24. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy [review] . Int J Oncol 2003;22:237-52.
25. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
26. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996;12:1397-403.
27. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40.
28. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95:1897-905.
29. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000;82:1991-9.
30. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-65.
31. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-48.
32. Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 2000; 86:307-17.
33. Yamazaki T, Hibi K, Takase T, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002;8:192-5.
34. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000;6:4764-7.
35. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001; 61:7908-12.
36. Liu Y, Lashuel HA, Choi S, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 2003;10:837-46.
37. Yin Z, Ivanov VN, Habelhah H, Tew K, Ronai Z. Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases. Cancer Res 2000; 60:4053-7.
38. Dulhunty A, Gage P, Curtis S, Chelvanayagam G, Board P. The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator. J Biol Chem 2001;276:3319-23.
39. Boss EA, Peters WH, Roelofs HM, Boonstra H, Steegers EA, Massuger LF. Glutathione S-transferases P1-1 and A1-1 in ovarian cyst fluids. Eur J Gynaecol Oncol 2001;22:427-32.
40. Miyanishi K, Takayama T, Ohi M, et al. Glutathione S transferase-π overexpression is closely associated with K-ras mutation during human colon carcinogenesis. Gastroenterology 2001;121:865-74.
41. Harbottle A, Daly AK, Atherton K, Campbell FC. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 2001;92: 777-83.
42. Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO J 1999;18:1321-34.
43. Ali-Osman F, Brunner JM, Kutluk TM, Hess K. Prognostic significance of glutathione S-transferase π expression and subcellular localization in human gliomas. Clin Cancer Res 1997;3:2253-61.
44. Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 1996;35: 243-82.
45. Bratt T. Lipocalins and cancer. Biochim Biophys Acta 2000; 1482:318-26.
46. Kato K, Ito H, Iwamoto I, Lida K, Inaguma Y. Protein kinase inhibitors can suppress stress-induced dissociation of Hsp27. Cell Stress Chaperones 2001;6:16-20.
47. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003;2:579-84.
48. Hino M, Kurogi K, Okubo MA, Murata-Hori M, Hosoya H. Small heat shock protein 27 (HSP27) associates with tubulin/microtubules in HeLa cells. Biochem Biophys Res Commun 2000;271:164-9.
49. Oesterreich S, Wang CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993;53: 4443-8.